Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.35 |
| ▸ | AURKA | O14965 | 2/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 2/20 | 0.35 |
| ▸ | FYN | P06241 | 2/20 | 0.35 |
| ▸ | CSF1R | P07333 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 2/20 | 0.35 |
| ▸ | IGF1R | P08069 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 2/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | FLT1 | P17948 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.35 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.35 |
| ▸ | NEK2 | P51955 | 2/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12109162 | 0.89 | KMT2A (0.39) | KDRLMNAHTTMAPTMEN1 | |
| SCHEMBL13152657 | 0.89 | GSK3B (0.37) | GSK3BAURKAMAP4K4ABL1NTRK1 | |
| SCHEMBL10097408 | 0.88 | ALDH1A1 (0.38) | AURKALMNAHTTGAAMAPT | |
| SCHEMBL10097437 | 0.88 | HDAC1 (0.41) | KDRLMNAHTTMAPTMEN1 | |
| SCHEMBL10096426 | 0.87 | PFKFB2 (0.38) | METKDRLMNAHTTGAA | |
| SCHEMBL13152716 | 0.87 | SMN1; SMN2 (0.35) | GAAMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13151819 | 0.86 | LMNA (0.37) | GSK3BAURKAMAP4K4ABL1NTRK1 | |
| SCHEMBL14467737 | 0.86 | ALDH1A1 (0.38) | LMNAHTTGAAMAPTMEN1 | |
| SCHEMBL13152678 | 0.85 | ALDH1A1 (0.38) | HTTGAAMAPTMEN1KMT2A | |
| SCHEMBL13152745 | 0.83 | HPGD (0.41) | KDRMAPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | GSK3B 1032/4885AURKA 4312/4885MAP4K4 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.